Evolus Stock News

OPKO Health (NASDAQ:OPK) and Evolus (NASDAQ:EOLS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, risk and earnings. Valuation & Earnings This table compares OPKO Health and Evolus revenue, earnings per share (EPS) and valuation. []

Evolus Inc. (NASDAQ:EOLS) concluded the trading at $5.37 on Friday, December 03 with a fall of -3.94% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $5.59 and 5Y monthly beta was reading 2.40 with its price kept floating in the range Evolus Inc. (EOLS) Analyst Thoughts: How High Can It Go? Read More »

During the last session, Evolus Inc. (NASDAQ:EOLS)s traded shares were 0.32 million, with the beta value of the company hitting 2.29. At the end of the trading day, the stocks price was $6.06, reflecting an intraday gain of 0.83% or $0.05. The 52-week high for the EOLS share is $17.38, that puts it down -186.8 We Just Learned Something New! After Evolus Inc. (NASDAQ: EOLS)s -10.62% Loss This Week Read More »

Virtu Financial LLC lowered its position in shares of Evolus, Inc. (NASDAQ:EOLS) by 5.7% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 29,348 shares of the companys stock after selling 1,789 shares during the quarter. Virtu Financial LLC owned about 0.05% of Evolus worth $371,000 as []

Equities research analysts predict that Evolus, Inc. (NASDAQ:EOLS) will announce ($0.36) earnings per share for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Evolus’ earnings, with estimates ranging from ($0.65) to ($0.21). Evolus posted earnings of ($0.73) per share in the same quarter last year, which indicates a positive year […]

Cubist Systematic Strategies LLC raised its holdings in shares of Evolus, Inc. (NASDAQ:EOLS) by 565.1% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 76,148 shares of the companys stock after purchasing an additional 64,699 shares during the period. Cubist Systematic Strategies LLCs holdings in Evolus were worth $963,000 at the end of the most []

Zacks Investment Research upgraded shares of Evolus (NASDAQ:EOLS) from a sell rating to a hold rating in a research report released on Friday morning, Zacks.com reports. According to Zacks, Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic []

Related Stocks: EOLS , TUEM , SDC , CTRN , MDXG , VST , MTNB ,

Evolus, Inc. (EOLS) CEO David Moatazedi on Q3 2021 Results - Earnings Call Transcript

NEWPORT BEACH, Calif., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today

NEWPORT BEACH, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today

Evolus, Inc. (EOLS) CEO David Moatazedi on Q2 2021 Results - Earnings Call Transcript

Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -12.50% and 2.32%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Record Quarter: Net Revenue Grew 235% Year-over-Year to $26.1 Million

This small-cap stock is going after a billion-dollar market.